ביבליוגרפיה

1. SYNVISC/Synvisc-One European Prescribing Information. Naarden, The Netherlands; Genzyme Europe B.V.; 2010.
2. Balazs EA, Watson D, Duff IF, Roseman S. Hyaluronic acid in synovial fluid, I: molecular parameters of hyaluronic acid in normal and arthritic human fluids. Arthritis Rheum. 1967;10(4):357-376.
3. Raynauld J-P, Torrance GW, Band PA, et al; Canadian Knee OA Study Group. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the
treatment paradigm for patients with knee osteoarthritis (part 1 of 2): clinical results. Osteoarthritis Cartilage. 2002;10(7):506-517.
4. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee—a prospective randomized clinical
trial. Knee 2008;15(4):318-324. doi:10.1016/j.knee.2008.02.012.
5. Waddell DD, Bricker DC. Total knee replacement delayed with hylan G-F20 use in patients with grade IV osteoarthritis. J Manag Care Pharm. 2007:13(2)113-121.
6. Bellamy N, Campbell J, Welch V, Gee TL, Bourne R, Wells GA Cochrane Database of Systematic Reviews2006, Issue 2. Art. No.: CD005321. DOI: 10.1002/14651858.CD005321.pub2.